Caliway Biopharmaceuticals (TWSE: 6919) announced that clinical results from its CBL-0204 Phase 2b study of drug candidate CBL-514 for fat ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE